Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy

Clinical validation of a noninvasive prenatal test for genomewide detection of fetal copy number variants

(2016) Roy B. Lefkowitz et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Anti-programmed cell death-1 therapy in nonmelanoma skin cancer

(2016) J.K. Winkler et al.   BRITISH JOURNAL OF DERMATOLOGY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

(2016) M. Schwaederle et al.   MOLECULAR CANCER THERAPEUTICS

Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma

(2015) Scott X. Atwood et al.   CANCER CELL

Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma

(2015) Hayley J. Sharpe et al.   CANCER CELL

Detection of Fetal Subchromosomal Abnormalities by Sequencing Circulating Cell-Free DNA from Maternal Plasma

(2015) C. Zhao et al.   CLINICAL CHEMISTRY

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

(2015) Michael R Migden et al.   LANCET ONCOLOGY

Skin Cancer Epidemiology, Detection, and Management

(2015) Sumul Ashok Gandhi et al.   MEDICAL CLINICS OF NORTH AMERICA

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients

(2015) M. Schwaederle et al.   MOLECULAR CANCER THERAPEUTICS

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

(2015) Michael T. Barrett et al.   Oncotarget

Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations

(2014) J. Wheler et al.   CANCER RESEARCH

Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience

(2014) M. Schwaederle et al.   ONCOLOGIST

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

(2012) Aleksandar Sekulic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD